Merck KGaA (OTCMKTS:MKGAF – Get Free Report) was upgraded by stock analysts at The Goldman Sachs Group to a “strong-buy” rating in a note issued to investors on Thursday, Zacks.com reports.
Merck KGaA Stock Performance
OTCMKTS:MKGAF opened at $189.00 on Thursday. The firm has a market capitalization of $24.43 billion, a PE ratio of 27.75 and a beta of 0.96. The company has a quick ratio of 0.84, a current ratio of 1.31 and a debt-to-equity ratio of 0.27. Merck KGaA has a 12-month low of $143.46 and a 12-month high of $200.56. The firm has a 50-day moving average price of $182.06 and a 200 day moving average price of $175.32.
Merck KGaA (OTCMKTS:MKGAF – Get Free Report) last issued its earnings results on Thursday, August 1st. The company reported $1.51 earnings per share (EPS) for the quarter. The business had revenue of $5.76 billion during the quarter. Merck KGaA had a return on equity of 10.17% and a net margin of 12.60%. Research analysts anticipate that Merck KGaA will post 9.5 earnings per share for the current fiscal year.
Merck KGaA Company Profile
Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector.
Recommended Stories
- Five stocks we like better than Merck KGaA
- Bank Stocks – Best Bank Stocks to Invest In
- Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
- 3 Grocery Stocks That Are Proving They Are Still Essential
- How the Fed’s Rate Cut Could Supercharge These 3 ETFs
- Options Trading – Understanding Strike Price
- Microsoft Stock: 3 Reasons It’s Ready to Crush Q4
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.
